CombiMatrix has announced that the validation study performed by its wholly-owned subsidiary, Combimatrix Molecular Diagnostics (CMDX), in collaboration with the Department of Pathology at the University of Texas Health Science Center in San Antonio, TX (Uthscsa), is now available.
Amit Kumar, President and CEO of CombiMatrix stated: As we continue to develop, launch, and validate ourtests, the oncology market will become a major focus and opportunity for us. While we have tests available for developmental genetic analysis, during the next few months we will be leveraging our first to market status and strong publication record of our cancer array tests to refocus our efforts on oncology. Such a redirection of resources will also include additional effort on our non-invasive screen for cancer.